Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study

Research output: Contribution to journalArticlepeer-review

Standard

Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study. / Bradwell, Arthur R; Ashdown, Kimberley; Rue, Carla; Delamere, John; Thomas, Owen D; Lucas, Samuel J E; Wright, Alex D; Harris, Stephen J; Myers, Stephen D; Birmingham Medical Research Expeditionary Society.

In: BMJ Open Sport & Exercise Medicine, Vol. 4, No. 1, 23.01.2018, p. e000302.

Research output: Contribution to journalArticlepeer-review

Harvard

Bradwell, AR, Ashdown, K, Rue, C, Delamere, J, Thomas, OD, Lucas, SJE, Wright, AD, Harris, SJ, Myers, SD & Birmingham Medical Research Expeditionary Society 2018, 'Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study', BMJ Open Sport & Exercise Medicine, vol. 4, no. 1, pp. e000302. https://doi.org/10.1136/bmjsem-2017-000302

APA

Bradwell, A. R., Ashdown, K., Rue, C., Delamere, J., Thomas, O. D., Lucas, S. J. E., Wright, A. D., Harris, S. J., Myers, S. D., & Birmingham Medical Research Expeditionary Society (2018). Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study. BMJ Open Sport & Exercise Medicine, 4(1), e000302. https://doi.org/10.1136/bmjsem-2017-000302

Vancouver

Author

Bradwell, Arthur R ; Ashdown, Kimberley ; Rue, Carla ; Delamere, John ; Thomas, Owen D ; Lucas, Samuel J E ; Wright, Alex D ; Harris, Stephen J ; Myers, Stephen D ; Birmingham Medical Research Expeditionary Society. / Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study. In: BMJ Open Sport & Exercise Medicine. 2018 ; Vol. 4, No. 1. pp. e000302.

Bibtex

@article{8099d757d0d54c83ba5f5cc6baa5b50a,
title = "Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study",
abstract = "Objective: To assess whether acetazolamide (Az), used prophylactically for acute mountain sickness (AMS), alters exercise capacity at high altitude.Methods: Az (500 mg daily) or placebo was administered to 20 healthy adults (aged 36±20 years, range 21-77), who were paired for age, sex, AMS susceptibility and weight, in a double-blind, randomised manner. Participants ascended over 5 days to 4559 m, then exercised to exhaustion on a bicycle ergometer, while recording breath-by-breath gas measurements. Comparisons between groups and matched pairs were done via Mann-Whitney U and Pearson's χ2 tests, respectively.Results: Comparing paired individuals at altitude, those on Az had greater reductions in maximum power output (Pmax) as a percentage of sea-level values (65±14.1 vs 76.6±7.4 (placebo); P=0.007), lower VO2max (20.7±5.2 vs 24.6±5.1 mL/kg/min; P<0.01), smaller changes from rest to Pmax for VO2 (9.8±6.2 vs 13.8±4.9 mL/kg/min; P=0.04) and lower heart rate at Pmax (154±25 vs 167±16, P<0.01) compared with their placebo-treated partners. Correlational analysis (Pearson's) indicated that with increasing age Pmax (r=-0.83: P<0.005) and heart rate at Pmax (r=-0.71, P=0.01) reduced more in those taking Az.Conclusion: Maximum exercise performance at altitude was reduced more in subjects taking Az compared with placebo, particularly in older individuals. The age-related effect may reflect higher tissue concentrations of Az due to reduced renal excretion. Future studies should explore the effectiveness of smaller Az doses (eg, 250 mg daily or less) in older individuals to optimise the altitude-Az-exercise relationships.",
author = "Bradwell, {Arthur R} and Kimberley Ashdown and Carla Rue and John Delamere and Thomas, {Owen D} and Lucas, {Samuel J E} and Wright, {Alex D} and Harris, {Stephen J} and Myers, {Stephen D} and {Birmingham Medical Research Expeditionary Society}",
year = "2018",
month = jan,
day = "23",
doi = "10.1136/bmjsem-2017-000302",
language = "English",
volume = "4",
pages = "e000302",
journal = "BMJ Open Sport & Exercise Medicine",
issn = "2055-7647",
publisher = "BMJ Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Acetazolamide reduces exercise capacity following a 5-day ascent to 4559 m in a randomised study

AU - Bradwell, Arthur R

AU - Ashdown, Kimberley

AU - Rue, Carla

AU - Delamere, John

AU - Thomas, Owen D

AU - Lucas, Samuel J E

AU - Wright, Alex D

AU - Harris, Stephen J

AU - Myers, Stephen D

AU - Birmingham Medical Research Expeditionary Society

PY - 2018/1/23

Y1 - 2018/1/23

N2 - Objective: To assess whether acetazolamide (Az), used prophylactically for acute mountain sickness (AMS), alters exercise capacity at high altitude.Methods: Az (500 mg daily) or placebo was administered to 20 healthy adults (aged 36±20 years, range 21-77), who were paired for age, sex, AMS susceptibility and weight, in a double-blind, randomised manner. Participants ascended over 5 days to 4559 m, then exercised to exhaustion on a bicycle ergometer, while recording breath-by-breath gas measurements. Comparisons between groups and matched pairs were done via Mann-Whitney U and Pearson's χ2 tests, respectively.Results: Comparing paired individuals at altitude, those on Az had greater reductions in maximum power output (Pmax) as a percentage of sea-level values (65±14.1 vs 76.6±7.4 (placebo); P=0.007), lower VO2max (20.7±5.2 vs 24.6±5.1 mL/kg/min; P<0.01), smaller changes from rest to Pmax for VO2 (9.8±6.2 vs 13.8±4.9 mL/kg/min; P=0.04) and lower heart rate at Pmax (154±25 vs 167±16, P<0.01) compared with their placebo-treated partners. Correlational analysis (Pearson's) indicated that with increasing age Pmax (r=-0.83: P<0.005) and heart rate at Pmax (r=-0.71, P=0.01) reduced more in those taking Az.Conclusion: Maximum exercise performance at altitude was reduced more in subjects taking Az compared with placebo, particularly in older individuals. The age-related effect may reflect higher tissue concentrations of Az due to reduced renal excretion. Future studies should explore the effectiveness of smaller Az doses (eg, 250 mg daily or less) in older individuals to optimise the altitude-Az-exercise relationships.

AB - Objective: To assess whether acetazolamide (Az), used prophylactically for acute mountain sickness (AMS), alters exercise capacity at high altitude.Methods: Az (500 mg daily) or placebo was administered to 20 healthy adults (aged 36±20 years, range 21-77), who were paired for age, sex, AMS susceptibility and weight, in a double-blind, randomised manner. Participants ascended over 5 days to 4559 m, then exercised to exhaustion on a bicycle ergometer, while recording breath-by-breath gas measurements. Comparisons between groups and matched pairs were done via Mann-Whitney U and Pearson's χ2 tests, respectively.Results: Comparing paired individuals at altitude, those on Az had greater reductions in maximum power output (Pmax) as a percentage of sea-level values (65±14.1 vs 76.6±7.4 (placebo); P=0.007), lower VO2max (20.7±5.2 vs 24.6±5.1 mL/kg/min; P<0.01), smaller changes from rest to Pmax for VO2 (9.8±6.2 vs 13.8±4.9 mL/kg/min; P=0.04) and lower heart rate at Pmax (154±25 vs 167±16, P<0.01) compared with their placebo-treated partners. Correlational analysis (Pearson's) indicated that with increasing age Pmax (r=-0.83: P<0.005) and heart rate at Pmax (r=-0.71, P=0.01) reduced more in those taking Az.Conclusion: Maximum exercise performance at altitude was reduced more in subjects taking Az compared with placebo, particularly in older individuals. The age-related effect may reflect higher tissue concentrations of Az due to reduced renal excretion. Future studies should explore the effectiveness of smaller Az doses (eg, 250 mg daily or less) in older individuals to optimise the altitude-Az-exercise relationships.

U2 - 10.1136/bmjsem-2017-000302

DO - 10.1136/bmjsem-2017-000302

M3 - Article

C2 - 29387446

VL - 4

SP - e000302

JO - BMJ Open Sport & Exercise Medicine

JF - BMJ Open Sport & Exercise Medicine

SN - 2055-7647

IS - 1

ER -